AstraZeneca

Q1 2024 results

Retrieved on: 
Thursday, April 25, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Annual general meeting, Annual, Osimertinib, LAURA, Dive (Belgian band), Lung cancer, PTEN, NMOSD, CER, FY, Blas, Outline, Budesonide, Total revenue, Growth, AstraZeneca, ASCO, EVH, Acquisition, EPS, PNH, ALPHA, NSCLC, Pharmaceutical industry

The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler US rights

Key Points: 
  • The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler US rights
    As announced at the Annual General Meeting on 11 April 2024, the total dividend for FY 2024 will increase by $0.20 per share to $3.10 per share
    "AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter.
  • We are also looking forward to seeing the results of several other important trials throughout the year.
  • If foreign exchange rates for April 2024 to December 2024 were to remain at the average rates seen in March 2024, compared to the performance at CER it is anticipated that FY 2024 Total Revenue would incur a low single-digit adverse impact and Core EPS would incur a mid single-digit adverse impact (previously low single-digit).
  • AstraZeneca will host an Investor Day on 21 May 2024.

Global Peptide Synthesis Market Report 2024, with Revenue Data from 2020-2023, Forecasts and CAGRs Projections for 2024-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Pharmaceutical, Health, Novartis, Teva Pharmaceuticals, Intelligence, AbbVie, GCC, ESG, Peptide, Lilly, AstraZeneca, Fine chemical

For each of these areas, current products in the market are identified, measuring the market size and identifying potential market drivers.

Key Points: 
  • For each of these areas, current products in the market are identified, measuring the market size and identifying potential market drivers.
  • Forecasts for 2028 are attained by analyzing the current competitors' market shares for the base year of 2022.
  • By geographic region, the market is segmented into North America, Europe, Asia-Pacific and the Rest of World.
  • For market estimates, data is provided for 2022 as the base year, with estimates for 2023 and forecast values for 2028.

Pelthos Therapeutics Establishes Board of Directors

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, Pharmaceutical, Health, LLP, Salix Pharmaceuticals, MedImmune, Fortress Investment Group, Commercial, Abbott Laboratories, IPO, Senior, Sucampo Pharmaceuticals, Patient, GSK plc, Medicine, Marketing, Therapy, AstraZeneca, Pharmaceutical industry

Pelthos Therapeutics (Pelthos), a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens, today announced it has appointed five seasoned industry professionals to serve on its Board of Directors.

Key Points: 
  • Pelthos Therapeutics (Pelthos), a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens, today announced it has appointed five seasoned industry professionals to serve on its Board of Directors.
  • “These directors bring deep operational, clinical and commercialization experience to Pelthos as we approach an important inflection point,” said Scott Plesha, CEO of Pelthos.
  • He is also a member of the Board of Directors at Soleno Therapeutics and Amplo Biotechnology.
  • In addition, Mr. Pauls previously served as Chair of the Board of Directors of Mast Therapeutics and was a member of the Board of Directors of Zyla Life Sciences.

Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, LLP, Aurora Biosciences, Growth, AstraZeneca, Patient, Cooley LLP, Intellectual property, Biomedicine, Accounting, Therapy, Vertex Pharmaceuticals

Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO).

Key Points: 
  • Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO).
  • Mr. Krueger brings extensive experience from the life sciences industry that will be instrumental to Endeavor's continued growth and success.
  • “Chris is an extremely accomplished life sciences executive with a deep understanding of the corporate operations, development and strategy needs of a company like Endeavor BioMedicines,” said John Hood, Ph.D., Co-founder, CEO and Chairman, Endeavor BioMedicines.
  • “I’m very impressed with Endeavor BioMedicines, including their extraordinary leadership team, groundbreaking science and pipeline of prospective medicines,” said Mr. Krueger.

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

Retrieved on: 
Tuesday, April 16, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Janus, Third Rock Ventures, Cancer, SCCHN, Cell, Neck, Pembrolizumab, Merck & Co., Infection, Immunotherapy, PD-1, AstraZeneca, Patient, Wellington Management Company, Renal cell carcinoma, RCC, Melanoma, Head, Toxicity, Bristol Myers Squibb, Merck, NSCLC, Autoimmunity, NK, Lung cancer, Vaccine

Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.

Key Points: 
  • Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.
  • “We are delighted to have the continued support of RA Capital, and excited to add two top biopharmaceutical companies and experts in oncology to our investor syndicate,” said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • We are pleased to have investors with deep and hands-on expertise in the cytokine space recognizing our early clinical data and our differentiated approach.
  • Initial pharmacokinetic and pharmacodynamic data from the ongoing Phase 1a/1b clinical trial support AB248’s proof of mechanism and activity with a highly differentiated clinical profile.

NorthStar Appoints Peter Pfreundschuh to Board of Managers

Retrieved on: 
Monday, April 15, 2024
Research, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, CFO, Cancer, LLP, NorthStar, Johnson & Johnson, Business development, Health technology, Business, Growth, CDMO, Rider University, Sucampo Pharmaceuticals, Patient, SCMP, Radiopharmaceutical, MBA, Therapy, Ernst & Young, Certified Public Accountant, AstraZeneca, Pharmaceutical industry

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024.

Key Points: 
  • NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024.
  • "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar.
  • “2024 and the next few years will be critical for NorthStar,” said Frank Scholz, NorthStar President and Chief Executive Officer.
  • I look forward to Pete joining the NorthStar Board.”

AscellaHealth Expands Executive Team: Industry Veterans Lead Development and Implementation of End-to-End Payer Solutions and Pharmacy Operations to Control Specialty Spend

Retrieved on: 
Thursday, April 11, 2024
Professional Services, Health, Data Analytics, Health Insurance, Managed Care, Pharmaceutical, MCI Inc., Pharmacy, Bausch, LP, PBM, LDD, Bausch Health, Knowledge, Coventry Health Care, SVP, Patient, Multimedia, Quality of life, AstraZeneca

View the full release here: https://www.businesswire.com/news/home/20240411865111/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240411865111/en/
    Bob Gilkin, SVP, AscellaHealth, will design and lead the implementation of trade and specialty strategy positioning.
  • His strategic leadership will drive the implementation of innovative payer strategies and models, as well as facilitate partnerships with LDD contracts.
  • We look forward to sharing more information soon.”
    Seiden brings the expertise and strategic insights developed during his career in pharmacy operations with experience at BioMatrix Specialty Pharmacy and Elwyn Pharmacy.
  • This is a key market differentiator that will improve access to LDDs and specialized treatment for health plan members nationwide.”

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Retrieved on: 
Thursday, April 11, 2024
Health, FDA, General Health, Research, Science, Pharmaceutical, Biotechnology, Efficacy, Safety, Gastroenterology, HES, Chronic obstructive pulmonary disease, Sinusitis, Social media, Polyp (medicine), Pharmacokinetics, Rheumatology, Conference call, Asthma, TATE, AstraZeneca, FY, Hypereosinophilic syndrome, Death, ClinicalTrials.gov, Dermatology, Conference, COPD, Webcast, Growth, Disease, Vasculitis, Respiratory Medicine, EGPA, Immunology, Metabolism, Diagnosis, Biomarker, PD, Biopharmaceutical, Ageing, Pharmaceutical industry

TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.

Key Points: 
  • TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.
  • The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.
  • Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study).
  • Severe uncontrolled asthma in children: practical approach on diagnosis and management.

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Nucleic acid thermodynamics, Trial of the century, Plasma, DdPCR, Digital, DNA, Patient, AACR, EGFR, NSCLC, AstraZeneca, Liquid biopsy, Medical imaging

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
  • These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical setting.
  • Biodesix supported this research by providing the EGFRm testing using Droplet Digital™ PCR* (ddPCR™) on plasma samples collected prior to treatment and three and six weeks after treatment initiation.
  • EGFRm testing is offered in a clinical setting by Biodesix as part of the GeneStrat® ddPCR targeted mutation test.

AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, April 25, 2024
Trial of the century, Hepatocellular carcinoma, ASCO, Patient, Society, Annual general meeting, AstraZeneca, HCC

ROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31 to June 4, 2024.

Key Points: 
  • ROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31 to June 4, 2024.
  • C-CAR031 is based on a novel GPC3-targeting CAR-T designed by AstraZeneca (LSE/STO/Nasdaq: AZN) using their transforming growth factor-beta receptor II (TGFβRII) dominant negative armoring discovery platform and is manufactured by AbelZeta in China.
  • C-CAR031 is being developed in China under a co-development agreement between AbelZeta and AstraZeneca.1
    Details of the oral presentation are as follows:
    Abstract Title: "Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)."
  • Session Type and Title: Rapid Oral Abstract – Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary